Bruker (NASDAQ:BRKR) Price Target Lowered to $50.00 at Citigroup

Bruker (NASDAQ:BRKR) had its price objective dropped by Citigroup from $75.00 to $50.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the medical research company’s stock. Citigroup’s price target would indicate a potential upside of 31.41% from the stock’s previous close.

Several other equities research analysts also recently weighed in on the company. Barclays decreased their price objective on Bruker from $69.00 to $65.00 and set an “overweight” rating for the company in a report on Monday, February 10th. Stifel Nicolaus lowered their price objective on shares of Bruker from $70.00 to $57.00 and set a “hold” rating on the stock in a research report on Friday, February 14th. UBS Group started coverage on shares of Bruker in a report on Tuesday, December 10th. They issued a “neutral” rating and a $66.00 target price for the company. Guggenheim reiterated a “buy” rating on shares of Bruker in a research note on Monday, February 24th. Finally, Bank of America boosted their price target on Bruker from $78.00 to $80.00 and gave the company a “buy” rating in a research report on Friday, December 13th. Six equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $68.00.

Bruker Stock Performance

BRKR traded up $1.59 on Monday, reaching $38.05. The company had a trading volume of 1,442,442 shares, compared to its average volume of 1,402,902. The company has a quick ratio of 0.77, a current ratio of 1.60 and a debt-to-equity ratio of 1.15. Bruker has a 1 year low of $34.10 and a 1 year high of $91.34. The stock has a market capitalization of $5.77 billion, a PE ratio of 50.28, a P/E/G ratio of 2.16 and a beta of 1.18. The stock has a 50-day moving average price of $48.64 and a 200-day moving average price of $56.00.

Bruker (NASDAQ:BRKR) last posted its earnings results on Thursday, February 13th. The medical research company reported $0.76 earnings per share for the quarter, beating the consensus estimate of $0.75 by $0.01. Bruker had a return on equity of 21.01% and a net margin of 3.36%. As a group, research analysts forecast that Bruker will post 2.69 EPS for the current fiscal year.

Institutional Trading of Bruker

A number of institutional investors have recently added to or reduced their stakes in the stock. Eagle Bay Advisors LLC raised its stake in shares of Bruker by 2,324.1% during the 4th quarter. Eagle Bay Advisors LLC now owns 703 shares of the medical research company’s stock worth $41,000 after buying an additional 674 shares during the last quarter. UMB Bank n.a. lifted its holdings in Bruker by 37.5% in the 4th quarter. UMB Bank n.a. now owns 909 shares of the medical research company’s stock valued at $53,000 after purchasing an additional 248 shares in the last quarter. MassMutual Private Wealth & Trust FSB boosted its stake in shares of Bruker by 274.9% during the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 1,091 shares of the medical research company’s stock worth $46,000 after purchasing an additional 800 shares during the last quarter. Quadrant Capital Group LLC boosted its stake in shares of Bruker by 18.2% during the 4th quarter. Quadrant Capital Group LLC now owns 1,273 shares of the medical research company’s stock worth $75,000 after purchasing an additional 196 shares during the last quarter. Finally, GAMMA Investing LLC raised its position in shares of Bruker by 47.5% in the fourth quarter. GAMMA Investing LLC now owns 1,279 shares of the medical research company’s stock valued at $75,000 after buying an additional 412 shares during the last quarter. Hedge funds and other institutional investors own 79.52% of the company’s stock.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.